

Elena Sotillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4307594/publications.pdf>

Version: 2024-02-01

42
papers

4,153
citations

218592

26
h-index

265120

42
g-index

49
all docs

49
docs citations

49
times ranked

5825
citing authors

#	ARTICLE	IF	CITATIONS
1	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	7.7	997
2	c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> , 2019, 576, 293-300.	13.7	480
3	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	3.2	369
4	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	6.0	297
5	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	7.7	296
6	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	15.2	172
7	Pharmacologic control of CAR-T cell function using dasatinib. <i>Blood Advances</i> , 2019, 3, 711-717.	2.5	143
8	CAR T Cell Therapy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2018, 9, 2380.	2.2	107
9	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344.	15.2	105
10	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
11	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	6.6	80
12	G1 Cyclin/Cyclin-dependent Kinase-coordinated Phosphorylation of Endogenous Pocket Proteins Differentially Regulates Their Interactions with E2F4 and E2F1 and Gene Expression. <i>Journal of Biological Chemistry</i> , 2002, 277, 50263-50274.	1.6	78
13	Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E11-E13.	2.0	78
14	Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. <i>Oncogene</i> , 2011, 30, 2587-2594.	2.6	73
15	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> , 2020, 34, 1202-1207.	3.3	61
16	GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. <i>Cancer Cell</i> , 2022, 40, 53-69.e9.	7.7	60
17	CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	55
18	Shielding the messenger (RNA): microRNA-based anticancer therapies. , 2011, 131, 18-32.		52

#	ARTICLE	IF	CITATIONS
19	Analysis of Polymorphisms of the Vitamin D Receptor, Estrogen Receptor, and Collagen I??1 Genes and Their Relationship With Height in Children With Bone Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 780-786.	0.3	51
20	Genetic and Epigenetic Alterations of the Cell Cycle Regulators and Tumor Suppressor Genes in Pediatric Osteosarcomas. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 362-367.	0.3	51
21	A Dynamic Equilibrium between CDKs and PP2A Modulates Phosphorylation of pRB, p107 and p130. <i>Cell Cycle</i> , 2004, 3, 1320-1330.	1.3	47
22	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2019, 111, 970-982.	3.0	43
23	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. <i>Blood Cancer Discovery</i> , 2021, 2, 648-665.	2.6	37
24	Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	36
25	Telomerase Activity and Telomere Length in Primary and Metastatic Tumors from Pediatric Bone Cancer Patients. <i>Pediatric Research</i> , 2004, 55, 231-235.	1.1	35
26	B55Î± PP2A Holoenzymes Modulate the Phosphorylation Status of the Retinoblastoma-related Protein p107 and Its Activation. <i>Journal of Biological Chemistry</i> , 2010, 285, 29863-29873.	1.6	33
27	TNFâ€± promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemicâ€±onset juvenile idiopathic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 451-454.	0.6	29
28	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	0.6	28
29	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 2429-2441.	3.3	24
30	Direct long-read RNA sequencing identifies a subset of questionable exons likely arising from reverse transcription artifacts. <i>Genome Biology</i> , 2021, 22, 190.	3.8	20
31	Cyclin E and SV40 Small t Antigen Cooperate to Bypass Quiescence and Contribute to Transformation by Activating CDK2 in Human Fibroblasts*. <i>Journal of Biological Chemistry</i> , 2008, 283, 11280-11292.	1.6	18
32	The long reach of noncoding RNAs. <i>Nature Genetics</i> , 2011, 43, 616-617.	9.4	16
33	Coordinated Activation of the Origin Licensing Factor CDC6 and CDK2 in Resting Human Fibroblasts Expressing SV40 Small T Antigen and Cyclin E. <i>Journal of Biological Chemistry</i> , 2009, 284, 14126-14135.	1.6	13
34	Tilting MYC toward cancer cell death. <i>Trends in Cancer</i> , 2021, 7, 982-994.	3.8	12
35	p21WAF1 Mutation Is Not a Predominant Alteration in Pediatric Bone Tumors. <i>Pediatric Research</i> , 1998, 43, 393-395.	1.1	12
36	Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains. <i>Blood</i> , 2018, 132, 963-963.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Screening of the human tumor necrosis factor-alpha (TNF- α) gene promoter polymorphisms by PCR-DGGE analysis. Mutation Research - Mutation Research Genomics, 1999, 406, 121-125.	1.2	4
38	Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL. Blood, 2021, 138, 613-613.	0.6	4
39	Regulation of CD19 Exon 2 Inclusion in B-Lymphoid Cells By Splicing Factors and Epigenetic Marks. Blood, 2015, 126, 2425-2425.	0.6	3
40	The Importance of CD19 Exon 2 for Surface Localization: Closing the Ig-like Loop. Blood, 2015, 126, 3433-3433.	0.6	3
41	Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2019, 134, 749-749.	0.6	2
42	Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting. Blood, 2020, 136, 22-22.	0.6	0